Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

Last updated on July 2021

Recruitment

Recruitment Status: Recruiting
Estimated Enrollment: Same as current

Summary

Conditions: Peripheral T Cell Lymphoma
Design: Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age: Between 18 years and 125 years
Gender: Both males and females

Description

Peripheral T-cell non-Hodgkin lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorder arising from mature T cells of post-thymic origin at different stages of differentiation with different morphological patterns, phenotypes, and clinical presentation. All subtypes are found more commonly in male patients, and the median age at diagnosis is 62 years. This disease is generally associated with high relapse rates and a poor prognosis, with inferior treatment outcomes compared with B-cell lymphomas and have a 5-year-survival < 32%. T-cell lymphomas are widely recognized as a complex and heterogeneous group of lymphoproliferative disorders, generally associated with high relapse rates and a poor prognosis. Because of their rarity, they are still very poorly understood. The introduction of new and more effective therapies and better technologies led the International T-cell non-Hodgkin's Lymphoma Study Group to launch the T-cell Project 2.0 in order to have a contemporary, real-time understanding of the T-cell lymphoma biology and treatment, together with the application of contemporary technologies to further identification of new therapeutic targets. Per protocol, patients are evaluated according to the treating physician's standard practice. There are no specific evaluations or visits required for the Registry. Data captured in the Registry reflects what is routinely collected for patients with PTCL. The study plans to collect the tissue sample for central review. The ordinary fixation, cryopreservation and routine tumor cytogenetics are planned for biopsy samples. Chairmen of the Histopathology Review Panel will locate Regional sites where expert hematopathologists will review the material and perform a panel of immunostains (T-cell panel + CD20) and markers not assessed at local site. Adding of blood sample collection will allow estimating prospectively the frequency of pEBVd detection in our cohort of PTCL patients at baseline and at the end of initial therapy, to characterize agreement between pEBVd and EBER in tumor tissue, and to explore the prognostic or predictive implications of detectable pEBVd in PTCL. Finally, to investigate the genetics and pathogenic mechanisms of aggressive PTCLs on an international scale.

Tracking Information

NCT #: NCT03964480
Collaborators: Not Provided
Investigators: Study Director: Massimo Federico, MD University of Modena and Reggio Emilia, Centro Oncologico Modenese, Modena, Italy Principal Investigator: Attilio Guarini, MD U.O. Ematologia, IRCCS Istituto Tumori "Giovanni Paolo II" Principal Investigator: Julie Vose, MD Section of Hematology/Oncology, Nebraska Medical Center, USA Principal Investigator: Steven Horwitz, MD Memorial Sloan Kettering Cancer Center Principal Investigator: Miles Prince, MD Peter MacCallum Cancer Center, Melbourne, Australia Principal Investigator: Kim Won Seog, MD Hematology-Oncology Samsung Medical Center, Seoul, South Korea Principal Investigator: Dolores Caballero, MD Instituto Biosanitaria de Salamanca, Salamanca, Spain Principal Investigator: Francesco Zaya, MD Azienda Sanitaria Universitaria Integrata S.M. Misericordia, Udine, Italy Principal Investigator: Stefano Luminari, MD S.C. Ematologia, Arcispedale S. Maria Nuova-IRCCS, Reggio Emilia, Italy Principal Investigator: Ranjana Advani, MD Stanford University Medical Center, Stanford, CA, USA Principal Investigator: Andrei Shustov, MD Seattle Cancer Care Alliance, Seattle, WA, USA Principal Investigator: Pierluigi Porcu, MD Hematopoietic Stem Cell Transplantation, Sidney Kimmel Cancer Center, USA Principal Investigator: Astrid Pavlovsky, MD Centro de Hematologia, FUNDALEU, Buenos Aires, Argentina Principal Investigator: Carlos Chiattone, MD Departamento de Clinica Médica, FCM da Santa Casa de Sao Paulo, Sao Paulo, Brazil Principal Investigator: Francine Foss, MD Yale University School of Medicine, New Haven, CT, USA Principal Investigator: Christopher Fox, MD Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK